BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. 1994

M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Second Department of Internal Medicine, Yokohama Minami Kyousai Hospital, Japan.

The pharmacokinetics of imipenem/cilastatin were determined in 7 critically ill patients undergoing slow hemodialysis (HD). All patients were anuric. Following intravenous administration of 500 mg of imipenem/cilastatin, concentrations of the drugs in the serum and dialysate were monitored during slow HD. The elimination phase half-life of imipenem was 3.1 +/- 0.3 h and that of cilastatin was 9.7 +/- 1.2 h. The total body clearance of imipenem and cilastatin was 84.0 +/- 7.2 and 32.2 +/- 2.4 ml/min, respectively. Clearance of imipenem and cilastatin during slow HD was 24.3 +/- 2.4 and 54.3 +/- 3.1%, respectively, of total body clearance. After the 10.5-h session of slow HD, serum concentrations of imipenem and cilastatin were 2.3 +/- 0.4 and 16.0 +/- 1.2 mg/l, respectively. It appears that at least 500 mg of imipenem may be needed as a supplemental dose after a session of slow HD or the application interval should be shortened to maintain a therapeutic concentration.

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077728 Cilastatin, Imipenem Drug Combination Combination of imipenem and cilastatin that is used in the treatment of bacterial infections; cilastatin inhibits renal dehydropeptidase I to prolong the half-life and increase the tissue penetration of imipenem, enhancing its efficacy as an anti-bacterial agent. Imipenem - Cilastatin,Imipenem - Cilastatin Sodium,Imipenem Cilastatin,Imipenem Cilastatin Sodium,Imipenem-Cilastatin,Imipenem-Cilastatin Sodium,Imipenem-Cilastatin, Sodium Salt,MK 0787-MK 0791 mixture,MK 787-MK 791 mixture,Primaxin,Thienam,Tienam 500,Zienam,Cilastatin, Imipenem,Imipenem Cilastatin, Sodium Salt,MK 0787 MK 0791 mixture,MK 787 MK 791 mixture

Related Publications

M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.
January 1997, ASAIO journal (American Society for Artificial Internal Organs : 1992),
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
December 1997, Antimicrobial agents and chemotherapy,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Imipenem/cilastatin/relebactam pharmacokinetics in critically ill patients with augmented renal clearance.
October 2022, The Journal of antimicrobial chemotherapy,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients.
March 2024, Journal of global antimicrobial resistance,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Population pharmacokinetic modeling of multiple-dose intravenous fosfomycin in critically ill patients during continuous venovenous hemodialysis.
October 2023, Scientific reports,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Pharmacokinetic studies of imipenem/cilastatin in elderly patients.
December 1986, The Journal of antimicrobial chemotherapy,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
July 1990, The Journal of antimicrobial chemotherapy,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis.
January 2005, Clinical pharmacokinetics,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency.
June 1985, The American journal of medicine,
M Kihara, and Y Ikeda, and K Shibata, and S Masumori, and H Ebira, and K Shiratori, and S Ueda, and N Takagi, and S Umemura, and H Shionoiri
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.
June 1985, The American journal of medicine,
Copied contents to your clipboard!